Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation

References

• TunnUWWiedeyKSafety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in EuropeProstate Cancer P D20091218387
   PubMed Web of Science ®Google Scholar
• AndroustosGJohn Hunter (1728–1793): fondateur de la chirugie scientifque etpercurseur de l’urologicProg Urol19988108710969894276
   PubMedGoogle Scholar
• HugginsCHodgesCVStudies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostateCancer Res19411293297
   Google Scholar
• HugginsCStevensREHodgesCVStudies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate glandArch Surg-Chicago194143209228
   Google Scholar
• WeinLRKAlanJNovickAndrew CPartinAlan WPetersCraig ACampbell-Walsh Urology9th edPhiladelphia, PAElsevier2007
   Google Scholar
• SchallyAVKastinAJArimuraAHypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studiesFertil Steril197122117037214941683
   PubMed Web of Science ®Google Scholar
• SeidenfeldJSamsonDJHasselbladVSingle-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysisAnn Intern Med2000132756657710744594
   PubMed Web of Science ®Google Scholar
• CoxMCScriptureCDFiggWDLeuprolide acetate given by a subcutaneous extended-release injection: less of a pain?Expert Rev Anticancer Ther20055460561116111462
   PubMed Web of Science ®Google Scholar
• CrawfordEDPhillipsJMSix-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfortCancer Manag Res2011320120921847353
   PubMedGoogle Scholar
• MottetNBellmuntJBollaMEAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201159457258321315502
   PubMed Web of Science ®Google Scholar
• PersadRLeuprorelin acetate in prostate cancer: a European updateInt J Clin Pract200256538939612137449
   PubMed Web of Science ®Google Scholar
• LabrieFMedical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancerJ Androl200425330531315064303
   PubMedGoogle Scholar
• LockeJAGunsESLubikAAAndrogen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancerCancer Res200868156407641518676866
   PubMed Web of Science ®Google Scholar
• ShoreNMasonMde ReijkeTMNew developments in castrate-resistant prostate cancerBJU Int2012109Suppl 6223222672122
   PubMed Web of Science ®Google Scholar
• CannataDHKirschenbaumALevineACAndrogen deprivation therapy as primary treatment for prostate cancerJ Clin Endocrinol Metab201297236036522162475
   PubMed Web of Science ®Google Scholar
• LeeMBrownellerRWuZJungARatanawongCSharifiRTherapeutic effects of leuprorelin microspheres in prostate cancerAdv Drug Deliv Rev199728112113810837568
   PubMed Web of Science ®Google Scholar
• TombalBBergesREligard. Advantages for optimal testosterone controlEur Urol Suppl2007518900904
   Web of Science ®Google Scholar
• RavivarapuHBMoyerKLDunnRLSustained activity and release of leuprolide acetate from an in situ forming polymeric implantAAPS Pharm Sci Tech200011E1
   Google Scholar
• Perez-MarreroRTylerRCA subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancerExpert Opin Pharmacother20045244745714996640
   PubMed Web of Science ®Google Scholar
• SpitzAYoungJMLarsenLMattia-GoldbergCDonnellyJChwaliszKEfficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancerProstate Cancer P D20121519399
   PubMed Web of Science ®Google Scholar
• CrawfordDPhillipsESix-month gonadotropin releasing hormone (GnRH) agonist depots provide efiicacy, safety, convenience, and comfortCancer Manag Res20113120120921847353
   PubMedGoogle Scholar
• OuzaidIRoupretMThe role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the ‘ELIRE’ observational studyProg Urol2011211286687422035913
   PubMed Web of Science ®Google Scholar
• TunnUWA 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patientsBMC Urol2011111521801354
   PubMed Web of Science ®Google Scholar
• ChavezBReillyTManic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric historyJ Clin Psy2010711216961698
   Web of Science ®Google Scholar
• MostafaNChwaliszKLarsenLPharmacokinetics and Pharmacodynamics of Leuprolide Acetate 6-Month Depot in Patients With Prostate CancerJ Clinv Pharmacol2010501091
   Web of Science ®Google Scholar
• SethiRSanfilippoNSix-month depot formulation of leuprorelin acetate in the treatment of prostate cancerClin Interv Aging2009425926719554097
   PubMed Web of Science ®Google Scholar
• Eligard BergesRSUP (R) 6: achieving optimal testosterone control with the convenience of a twice -a-year formulationEur Urol Suppl2007615840845
   Web of Science ®Google Scholar
• CrawfordEDSartorOChuFPerezRKarlinGGarrettJSA 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol2006175253353616406989
   PubMed Web of Science ®Google Scholar
• AmoFHComparative analysis of six months formulation of LHRH analogues for prostate cancer treatmentArch Esp Urol201063427528120508303
   PubMedGoogle Scholar
• YoungJMSpitzALarsenLMattia-GoldbergCDonnellyJChwaliszKEfficacy and safety of a 6-month depot leuprolide acetate for the treatment of prostate cancer: results of a 48-week studyJ Clin Oncol2010Supplemente15042
   Web of Science ®Google Scholar
• KienleELubbenGEfficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study GroupUrol Int199656Suppl 123308776814
   PubMed Web of Science ®Google Scholar
• TunnUWBargelloniUCoscianiSFiaccaventoGGuazzieriSPaganoFComparison of LH–RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancerUrol Int199860Suppl 1916 discussion16179563139
   PubMed Web of Science ®Google Scholar
• JochamDLeuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up resultsUrol Int199860Suppl 21824 discussion359607554
   PubMed Web of Science ®Google Scholar
• Perez-MarrenoRChuFMGleasonDLoizidesEWachsBTylerRCA six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancerClin Ther200224111902191412501882
   PubMed Web of Science ®Google Scholar
• ChuFMJaysonMDineenMKPerezRHarkawayRTylerRCA clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancerJ Urol200216831199120312187267
   PubMed Web of Science ®Google Scholar
• SharifRSolowayMClinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study GroupJ Urol1990143168712104638
   PubMed Web of Science ®Google Scholar
• SharifRBruskewitzRCGittlemanMCGrahamSDJrHudsonPBSteinBLeuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClin Ther19961846476578879893
   PubMed Web of Science ®Google Scholar
• SharifRBrownellerRSerum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancerJ Urol200216831001100412187208
   PubMed Web of Science ®Google Scholar
• SchulmanCAssessing the attitudes to prostate cancer treatment among European male patientsBJU Int2007100Suppl 161117593202
   PubMed Web of Science ®Google Scholar
• OdeyemiIABergesRBolodeokuJEconomic impact of different preparations of leuprolide acetate in the management of advanced prostate cancerJ Med Econ2007102135146
   Google Scholar
• TundiaNLFuldeoreMGrucaDHassSBacherPBodhaniACost effectiveness of treatment with new 6-month leoprorelin acetate formulation in patients with advanced prostate cancerPaper presented at: ISPOR 15th Annual European Congress2012Berlin, Germany
   Google Scholar
• GrucaDBacherPTunnUSafety and tolerability of intermittent androgen deprivation therapy: a literature reviewInt J Urol201219761462522435512
   PubMed Web of Science ®Google Scholar
• D’AmicoAVWhittingtonRBruce MalkowiczSBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancerJAMA1998290119699749749478
   PubMed Web of Science ®Google Scholar